ClinicalTrials.gg
TerminatedNCT04922710PEACHUpdated Jun 6, 2024Results posted

Physical Exercise for Augmenting Cognitive Health (PEACH)

An Early Phase 1 interventional study of Home-based aerobic exercise in Cognitive Aging and Adverse Childhood Experiences, sponsored by University of Pittsburgh. Terminated at 2 sites in 2 countries. Open to participants aged 30 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-06.

Sponsored by University of Pittsburgh · Early Phase 1, Interventional, and Treatment

Why this study was terminated
The study protocol was not feasible. We made several modifications but halted the study prematurely before we met our target sample size goal.
Phase
Early Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
30 Years to 55 Years
Sex
All
01

Study summary

PEACH is a pilot project which is being conducted to determine the feasibility and acceptability of a 12-week home-based exercise intervention among Black and African American adults. A secondary aim of the project is to determine whether the exercise intervention improves cognitive and psychological functioning.

Read the detailed description

This pilot project aims to address the impact of early life adversity (ELA) on brain health in adulthood by conducting a pilot 12-week physical activity (PA) intervention delivered remotely using aerobic exercise bikes programmed to connect users with a trainer via an app. Investigators will recruit Black and African American individuals between the ages of 30-55 years (N = 40) who are currently sedentary and report experiencing at least one form of ELA prior to the age of 10. This study will be conducted at two sites: the University of Pittsburgh in Pittsburgh, PA, USA and the University of the West Indies in Kingston, Jamaica (site investigator: Terrence Forrester). At baseline and following the 12-week intervention, Investigators will collect a harmonized battery of cognitive, behavioral and psychosocial measures. The intervention itself will be home-based and will involve three 60-minute sessions of aerobic exercise per week using a Bluetooth-enable exercise bike. Participants' exercise programs will be supervised remotely by an exercise trainer and individualized depending on their age-adjusted heart rate reserve, with the goal being to have participants reach 50 minutes of moderate to vigorous intensity exercise per session by the end of the first 4 weeks of the intervention. The bikes will be outfitted with a tablet featuring an application called Neotiv. The Neotiv application will collect data from the bike regarding timing, duration, and intensity of exercise sessions, which will be securely shared with the exercise trainer to monitor attendance and adherence. The primary goals of this study are to determine whether the home-based exercise program (1) is feasible and acceptable (as measured by adherence and attendance), and (2) promotes improvements in cognitive and psychological functioning among adults who have been exposed to ELA, contingent on the feasibility. We realized that placing the health-related outcomes as primary or secondary outcomes would only make sense if the approach was feasible. Therefore, we revised the primary and secondary outcome measures to reflect the feasibility of the home-based exercise intervention program in terms of adherence and attendance.

02

Conditions studied

  • Cognitive Aging
  • Adverse Childhood Experiences

Browse trials for

Keywords

  • Adverse Childhood Experiences
  • Brain Health
  • Cognitive Aging
  • Exercise
  • Reversibility Network
03

In context

Motor Activity

9,798 studies on the registry are indexed under Motor Activity; 1,910 are open to participants now.

This study's enrollment of 8 is below the median of 60 across 8,388 interventional studies indexed under Motor Activity.

Browse Motor Activity studies →

Lead sponsor

University of Pittsburgh is the lead sponsor of 1,419 studies on the registry; 168 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. adults aged 30-55 years
  2. exposure to at least one form of threat-related adversity (e.g., exposure to violence; physical abuse) occurring prior to age 10 as documented by retrospective self-report
  3. Self-identified Black or African American Race
  4. access to high-speed internet
  5. sedentary lifestyle (\<60 minutes of PA/week).
  6. no difficulties with mobility
  7. Does not currently require the use of an assisted walking device
  8. Does not have a history of balance difficulties
  9. Not currently pregnant or planning to become pregnant in the next 12 months

Exclusion criteria

Exclusion Criteria:

  1. Psychosis
  2. Significant suicide risk (i.e., current, active suicidal ideation with a plan)
  3. Engaging in moderate-intensity exercise >=20 min per day, >=3 times per week
  4. Current treatment for cancer
  5. Neurological condition (MS, Parkinson's, Dementia, MCI) or brain injury (Stroke)
  6. Substance use disorder in the past 3-months
  7. Current treatment for congestive heart failure, angina, uncontrolled arrhythmia, deep vein thrombosis (DVT) or other cardiovascular event
  8. Myocardial infarction, coronary artery bypass grafting, angioplasty or other cardiac condition in the past year
  9. Sensory Impairment that would preclude neuropsychological testing
  10. Not fluent in English
  11. Travelling consecutively for 2+ weeks during the study
  12. uncontrolled hypertension
  13. Insulin-Dependent Diabetes Mellitus
  14. Self-identified race anything other than Black or African American
  15. Currently pregnant or planning to become pregnant in the next 12 months
05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Home-based aerobic exercise

    Un-supervised exercise will be held 3 times a week for 60 minutes in the participant's home. Those who are unable to do a 60-minute session would instead complete it in two 30-minute sessions to reach the goal of exercising 150 minutes per week.

    Behavioral: Home-based aerobic exercise

Interventions

  • BehavioralHome-based aerobic exercise

    Guidelines for exercise programming (ACSM, 2018) will be followed including a warmup and cool down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity related injury. The exercise group will receive moderate to vigorous intensity aerobic exercise for 60 minutes per day, three times a week, for 12 weeks. Participants who are unable to do a 60-minute session would instead complete it in two 30-minute sessions. The prescribed intensity will be based on estimated heart rate reserve, calculated using resting heart rate and age-adjusted heart rate maximum (220-age in years). Participants will maintain a minimum heart rate from their specific calculation that will be monitored by Polar Heart Rate straps.

06

What researchers measure

Primary outcomes

  1. Adherence to Exercise Intervention Program: Average Minutes Spent in Moderate to Vigorous Exercise

    Data regarding the average number of minutes spent engaging in moderate to vigorous exercise (via heart rate monitoring and comparison of heart rate to calculations based on heart rate reserve) will be collected to operationalize adherence. Adherence will be used as a metric of feasibility and acceptability.

    Time frame: baseline to 12 weeks

Secondary outcomes

  1. Adherence to Exercise Intervention Program: Number of Sessions Completed

    Data regarding the number of exercise sessions completed will be collected to operationalize adherence. Adherence will be used as a metric of feasibility and acceptability.

    Time frame: baseline to 12 weeks

Other outcomes

  1. Mean Change in Systolic Blood Pressure

    Systolic blood pressure (SBP) will be measured at baseline and 12-weeks to determine whether there is a change in SBP.

    Time frame: baseline to 12 weeks

  2. Mean Change in Physical Activity

    Participants will complete one week of actigraphy at baseline and again at follow-up to determine whether physical activity levels change. This will be operationalized as change in average number of steps per day.

    Time frame: baseline to 12 weeks

  3. Mean Change in Heart Rate

    Heart rate will be measured throughout the intervention and changes in heart rate from baseline to the end of the intervention will be calculated.

    Time frame: baseline to 12 weeks

  4. Percent Change in Total Body Weight

    Participants will be weighed on a calibrated stadiometer both before and after the intervention. The investigators will examine percent changes in body weight before and after the intervention.

    Time frame: baseline to 12 weeks

  5. Mean Change in Negative and Positive Affect

    This will be calculated via scores from the Positive and Negative Affect Scale. Scores can range from 1 to 100, with 1 meaning less positive affect and 100 meaning more positive affect.

    Time frame: baseline to 12 weeks

  6. Mean Change in Depressive Symptoms

    Participants will complete the Center for Epidemiological Studies-Depression Scale, a measure of the frequency of 20 common depressive symptoms rated along a 0 ("rarely or none of the time") to 3 ("most or all of the time") Likert scale. Responses are summed to yield a total symptom score (maximum possible score of 60) with higher scores reflecting more severe depressive symptoms.

    Time frame: baseline to 12 weeks

  7. Mean Change in Perceived Stress

    Participants will complete the Perceived Stress Scale (PSS) a measure of the frequency of 20 common depressive symptoms rated along a 0 ("rarely or non, a 14-item measure that assesses experiences of daily life stress. The PSS is an instrument on which respondents use a 0 ("never") to 4 ("very often") Likert scale to rate the degree to which daily life events are perceived to be uncontrollable, unpredictable, or unmanageable. Responses are summed to form a total score (maximum possible score of 56).

    Time frame: baseline to 12 weeks

  8. Mean Change in Picture Sequence Performance

    A Picture Sequence task will be administered at baseline, and then following the intervention (12-weeks). The main outcome from this task is the cumulative number of adjacent pictures in which a participant correctly remembered the sequence. A lower number of correct items indicates worse episodic memory.

    Time frame: baseline to 12 weeks

  9. Mean Change in Picture Vocabulary Performance

    A Picture Vocabulary task will be administered at baseline, and then following the intervention (12-weeks). Participants will be presented with visual stimuli along with an auditory cue and will have to judge which of the visual stimuli match the auditory cue. The main outcome from this task is total items answered correctly, with a lower number of items being indicative or worse language ability.

    Time frame: baseline to 12 weeks

  10. Mean Change in Pattern Comparison Performance

    A Pattern Comparison task will be administered at baseline, and then following the intervention (12-weeks). Participants will be presented with visual patterns and asked to respond whether the patterns are the same or different. The main outcome from this task is total items answered correctly in the 90 seconds allotted for the task, with a lower number of items being indicative or worse processing speed.

    Time frame: baseline to 12 weeks

  11. Adherence to Exercise Intervention Program: Average Duration of Sessions

    Data regarding the average duration of sessions will be collected to operationalize adherence. Adherence will be used as a metric of feasibility and acceptability.

    Time frame: baseline to 12 weeks

  12. Mean Change in Flanker Performance

    A Flanker task will be administered at baseline, and then following the intervention (12-weeks). The main outcome from this task is an interference effect (in ms) which indicates how much longer it takes for a participant to make a directional response to a center arrow when the flanking arrows are arranged in congruent vs. incongruent direction from the center stimulus. A higher interference effect indicates worse executive functioning.

    Time frame: baseline to 12 weeks

  13. Mean Change in Dimensional Card Sort Performance

    A Dimensional Card Sort task will be administered at baseline, and then following the intervention (12-weeks). The main outcome from this task is an interference effect (in ms) which indicates how much longer it takes for a participant to match a stimulus to other choice stimuli based on a feature (shape or color), with the feature participants must match on switching without warning during the task. A higher interference effect indicates worse executive functioning.

    Time frame: baseline to 12 weeks

  14. Mean Change in List Sorting Performance

    A List Sorting task will be administered at baseline, and then following the intervention (12-weeks). Participants will be presented with a series of stimuli and then be asked to repeat the stimuli in order of size from smallest to largest. The main outcome from this task is total items answered correctly, with a lower scoring being indicative or worse working memory.

    Time frame: baseline to 12 weeks

07

Results

Posted Jun 6, 2024

Participant flow

Participant flow — Overall Study
MilestoneHome-based Aerobic Exercise
Started5
Completed4
Not completed1

Outcome measures

PrimaryAdherence to Exercise Intervention Program: Average Minutes Spent in Moderate to Vigorous Exercise

Data regarding the average number of minutes spent engaging in moderate to vigorous exercise (via heart rate monitoring and comparison of heart rate to calculations based on heart rate reserve) will be collected to operationalize adherence. Adherence will be used as a metric of feasibility and acceptability.

Time frame:
baseline to 12 weeks
Reported as:
Mean · Minutes
Adherence to Exercise Intervention Program: Average Minutes Spent in Moderate to Vigorous Exercise
MinutesHome-based Aerobic Exercise
Adherence to Exercise Intervention Program: Average Minutes Spent in Moderate to Vigorous Exercise1578.5 ± 721.73
SecondaryAdherence to Exercise Intervention Program: Number of Sessions Completed

Data regarding the number of exercise sessions completed will be collected to operationalize adherence. Adherence will be used as a metric of feasibility and acceptability.

Time frame:
baseline to 12 weeks
Reported as:
Mean · Number of sessions
Adherence to Exercise Intervention Program: Number of Sessions Completed
Number of sessionsHome-based Aerobic Exercise
Adherence to Exercise Intervention Program: Number of Sessions Completed51.25 ± 13.15
Other pre-specifiedMean Change in Systolic Blood Pressure

Systolic blood pressure (SBP) will be measured at baseline and 12-weeks to determine whether there is a change in SBP.

Time frame:
baseline to 12 weeks

Results for this outcome have not been posted.

Other pre-specifiedMean Change in Physical Activity

Participants will complete one week of actigraphy at baseline and again at follow-up to determine whether physical activity levels change. This will be operationalized as change in average number of steps per day.

Time frame:
baseline to 12 weeks

Results for this outcome have not been posted.

Other pre-specifiedMean Change in Heart Rate

Heart rate will be measured throughout the intervention and changes in heart rate from baseline to the end of the intervention will be calculated.

Time frame:
baseline to 12 weeks

Results for this outcome have not been posted.

Other pre-specifiedPercent Change in Total Body Weight

Participants will be weighed on a calibrated stadiometer both before and after the intervention. The investigators will examine percent changes in body weight before and after the intervention.

Time frame:
baseline to 12 weeks

Results for this outcome have not been posted.

Other pre-specifiedMean Change in Negative and Positive Affect

This will be calculated via scores from the Positive and Negative Affect Scale. Scores can range from 1 to 100, with 1 meaning less positive affect and 100 meaning more positive affect.

Time frame:
baseline to 12 weeks

Results for this outcome have not been posted.

Other pre-specifiedMean Change in Depressive Symptoms

Participants will complete the Center for Epidemiological Studies-Depression Scale, a measure of the frequency of 20 common depressive symptoms rated along a 0 ("rarely or none of the time") to 3 ("most or all of the time") Likert scale. Responses are summed to yield a total symptom score (maximum possible score of 60) with higher scores reflecting more severe depressive symptoms.

Time frame:
baseline to 12 weeks

Results for this outcome have not been posted.

Other pre-specifiedMean Change in Perceived Stress

Participants will complete the Perceived Stress Scale (PSS) a measure of the frequency of 20 common depressive symptoms rated along a 0 ("rarely or non, a 14-item measure that assesses experiences of daily life stress. The PSS is an instrument on which respondents use a 0 ("never") to 4 ("very often") Likert scale to rate the degree to which daily life events are perceived to be uncontrollable, unpredictable, or unmanageable. Responses are summed to form a total score (maximum possible score of 56).

Time frame:
baseline to 12 weeks

Results for this outcome have not been posted.

Other pre-specifiedMean Change in Picture Sequence Performance

A Picture Sequence task will be administered at baseline, and then following the intervention (12-weeks). The main outcome from this task is the cumulative number of adjacent pictures in which a participant correctly remembered the sequence. A lower number of correct items indicates worse episodic memory.

Time frame:
baseline to 12 weeks

Results for this outcome have not been posted.

Other pre-specifiedMean Change in Picture Vocabulary Performance

A Picture Vocabulary task will be administered at baseline, and then following the intervention (12-weeks). Participants will be presented with visual stimuli along with an auditory cue and will have to judge which of the visual stimuli match the auditory cue. The main outcome from this task is total items answered correctly, with a lower number of items being indicative or worse language ability.

Time frame:
baseline to 12 weeks

Results for this outcome have not been posted.

Other pre-specifiedMean Change in Pattern Comparison Performance

A Pattern Comparison task will be administered at baseline, and then following the intervention (12-weeks). Participants will be presented with visual patterns and asked to respond whether the patterns are the same or different. The main outcome from this task is total items answered correctly in the 90 seconds allotted for the task, with a lower number of items being indicative or worse processing speed.

Time frame:
baseline to 12 weeks

Results for this outcome have not been posted.

Other pre-specifiedAdherence to Exercise Intervention Program: Average Duration of Sessions

Data regarding the average duration of sessions will be collected to operationalize adherence. Adherence will be used as a metric of feasibility and acceptability.

Time frame:
baseline to 12 weeks

Results for this outcome have not been posted.

Other pre-specifiedMean Change in Flanker Performance

A Flanker task will be administered at baseline, and then following the intervention (12-weeks). The main outcome from this task is an interference effect (in ms) which indicates how much longer it takes for a participant to make a directional response to a center arrow when the flanking arrows are arranged in congruent vs. incongruent direction from the center stimulus. A higher interference effect indicates worse executive functioning.

Time frame:
baseline to 12 weeks

Results for this outcome have not been posted.

Other pre-specifiedMean Change in Dimensional Card Sort Performance

A Dimensional Card Sort task will be administered at baseline, and then following the intervention (12-weeks). The main outcome from this task is an interference effect (in ms) which indicates how much longer it takes for a participant to match a stimulus to other choice stimuli based on a feature (shape or color), with the feature participants must match on switching without warning during the task. A higher interference effect indicates worse executive functioning.

Time frame:
baseline to 12 weeks

Results for this outcome have not been posted.

Other pre-specifiedMean Change in List Sorting Performance

A List Sorting task will be administered at baseline, and then following the intervention (12-weeks). Participants will be presented with a series of stimuli and then be asked to repeat the stimuli in order of size from smallest to largest. The main outcome from this task is total items answered correctly, with a lower scoring being indicative or worse working memory.

Time frame:
baseline to 12 weeks

Results for this outcome have not been posted.

Adverse events

Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Home-based Aerobic Exercise0/5 (0%)0/5 (0%)0/5 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Home-based Aerobic Exercise
Mean40.40 ± 9.94
Sex: Female, Male
Sex: Female, Male(Participants)Home-based Aerobic Exercise
Female4
Male1
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Home-based Aerobic Exercise
Hispanic or Latino0
Not Hispanic or Latino5
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Home-based Aerobic Exercise
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American5
White0
More than one race0
Unknown or Not Reported0
08

Study locations

2 sites
  • Sennott Square
    Pittsburgh, Pennsylvania 15220-2505, United States
  • University of the West Indies
    Kingston, Jamaica
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data from this study will be made available to outside investigators under a data-sharing agreement. The data will be available to outside investigators after publication of the primary aims and at completion of quality control assessments and data organization. The investigators expect that the data from this study will result in interest from internal and external investigators for secondary analysis and ancillary projects.

Supporting information: Study protocol, Clinical study report, Analytic code

Time frame: Will be made available after study investigators have published summary data and primary aims results. Will be available for unlimited amount of time.

Access criteria: Data requests will be approved by the PI and Co-PIs.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04922710
Responsible party
Kirk Erickson, PhD (Professor, University of Pittsburgh) — Principal investigator
First posted
Jun 11, 2021
Start date
Jan 4, 2022
Primary completion
May 3, 2023
Completion
May 30, 2023
Results posted
Jun 6, 2024
Last update
Jun 6, 2024

Study contacts

Kirk I Erickson, PhD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion